Remdesivir for the Treatment of COVID-19, its Safety and Clinical Effectiveness: A Clinical Review

References (44)

1. 1 Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China [DOI]
2. 2 Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study [DOI]
3. 3 Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study [DOI]
4. 4 Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia [DOI]
5. 5 An interactive web-based dashboard to track COVID-19 in real time [DOI]
6. 6 Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China [DOI]
7. 7 Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19) [DOI]
8. 8 Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy [DOI]
9. 9 Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial [DOI]
10. 10 Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results [DOI]
11. 11 Compassionate Use of Remdesivir for Patients with Severe Covid-19 [DOI]
12. 12 Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis [DOI]
13. 13 SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes [DOI]
14. 14 Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases [DOI]
15. 15 Nervous system involvement after infection with COVID-19 and other coronaviruses [DOI]
16. 16 Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys [DOI]
17. 17 Obesity in Patients Younger Than 60 Years Is a Risk Factor for COVID-19 Hospital Admission [DOI]
18. 18 SARS-CoV-2 Vaccines: Status Report [DOI]
19. 19 Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID-19 [DOI]
20. 20 Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study [DOI]
21. 21 The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus [DOI]
22. 22 Strategies in the design of antiviral drugs [DOI]
23. 23 The evolution of nucleoside analogue antivirals: A review for chemists and non-chemists. Part 1: Early structural modifications to the nucleoside scaffold [DOI]
24. 24 The SARS-CoV-2 Vaccine Pipeline: an Overview [DOI]
25. 25 Design, synthesis, and broad spectrum antiviral activity of 1-.beta.-D-ribofuranosyl-1,2,4-triazole-3-carboxamide and related nucleosides [DOI]
26. 26 Endocrine and metabolic link to coronavirus infection [DOI]
27. 27 Remdesivir (GS-5734) protects African green monkeys from Nipah virus challenge [DOI]
28. 28 Identification of 53 compounds that block Ebola virus-like particle entry via a repurposing screen of approved drugs [DOI]
29. 29 Remdesivir and its antiviral activity against COVID-19: A systematic review [DOI]
30. 30 Aryloxy Phosphoramidate Triesters: a Technology for Delivering Monophosphorylated Nucleosides and Sugars into Cells [DOI]
31. 31 Synthesis and antiviral activity of a series of 1′-substituted 4-aza-7,9-dideazaadenosine C-nucleosides [DOI]
32. 32 Ribavirin - current status of a broad spectrum antiviral agent [DOI]
33. 33 Response to Commentary on “The neuroinvasive potential of SARS‐CoV‐2 may play a role in the respiratory failure of COVID‐19 patients” [DOI]
34. 34 The pandemic pipeline [DOI]
35. 35 Safety and clinical outcomes of remdesivir in hospitalised COVID-19 patients: a retrospective analysis of active surveillance database [DOI]
36. 36 Pharmacokinetics and tissue distribution of remdesivir and its metabolites nucleotide monophosphate, nucleotide triphosphate, and nucleoside in mice [DOI]
37. 37 Minireview of progress in the structural study of SARS-CoV-2 proteins [DOI]
38. 38 Antimicrobial Strategies [DOI]
39. 39 Cell-based assays to identify inhibitors of viral disease [DOI]
40. 40 Remdesivir for the treatment of COVID 19: review of the pharmacological properties, safety and clinical effectiveness [DOI]
41. 41 Modeling the Potential Impact of Remdesivir Treatment for Hospitalized Patients with COVID-19 in Saudi Arabia on Healthcare Resource Use and Direct Hospital Costs: A Hypothetical Study [DOI]
42. 42 Evidence of the COVID-19 Virus Targeting the CNS: Tissue Distribution, Host–Virus Interaction, and Proposed Neurotropic Mechanisms [DOI]
43. 43 Neurological Manifestations of Hospitalized Patients with COVID-19 in Wuhan, China: A Retrospective Case Series Study [DOI]
44. 44 NCATS launches drug repurposing program [DOI]

Cited by 1

Related research

• Covid-2019:“A Microbiological Monster” — shares topic coverage
• COVID 19 Disease Caused by Coronavirus 2 (SARS-CoV-2) (Severe Acute Respiratory Syndrome) — shares topic coverage
• Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2): What Can Africa Learn from Ongoing Research in Epidemiology, Clinical Manifestations, Chemotherapy and Prevention? — shares topic coverage
• Azithromycin and Hydroxychloroquine Accelerate Recovery of Outpatients with Mild/Moderate COVID-19 — shares topic coverage
• Early Treatment with Hydroxychloroquine Improves Clinical Outcomes and Reduces Hospital Admissions in COVID-19 Associated Pneumonia — shares topic coverage